Medpace (NASDAQ:MEDP) CEO August Troendle Sells 4,000 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 4,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $620.03, for a total value of $2,480,120.00. Following the sale, the chief executive officer owned 540,544 shares in the company, valued at approximately $335,153,496.32. This represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Trading Down 1.2%

Shares of NASDAQ:MEDP opened at $611.57 on Friday. The company has a 50 day moving average of $562.52 and a 200 day moving average of $493.80. The stock has a market cap of $17.07 billion, a P/E ratio of 35.85, a P/E/G ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the subject of a number of research analyst reports. Mizuho lifted their price target on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Finally, BMO Capital Markets increased their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System raised its position in Medpace by 53,619.6% in the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after purchasing an additional 13,963,607 shares during the period. BlackRock Inc. purchased a new stake in Medpace during the second quarter valued at about $1,323,047,000. AQR Capital Management LLC boosted its position in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares during the period. Wasatch Advisors LP grew its stake in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.